A Subunit Vaccine Harboring the Fusion Capsid Proteins of Porcine Circovirus Types 2, 3, and 4 Induces Protective Immune Responses in a Mouse Model DOI Creative Commons

Qikai Wang,

Ran Zhang, Yue Wang

et al.

Viruses, Journal Year: 2024, Volume and Issue: 16(12), P. 1964 - 1964

Published: Dec. 23, 2024

Coinfections with porcine circovirus types 2, 3, and 4 (PCV2, PCV3, PCV4) are increasingly being detected in the swine industry. However, there is no commercially available vaccine which prevents coinfection PCV2, PCV4. The development of a expressing capsid (Cap) fusion proteins multiple PCVs represents promising approach for broadly preventing infection PCVs. In this study, we developed PCV subunit candidate (Cap 2-3-4) by predicting, screening, fusing antigenic epitopes Cap Immunoprotection assays showed that prokaryotic expression 2-3-4 could effectively induce high levels PCV4 Cap-specific antibodies successfully neutralize both PCV2 PCV3. Furthermore, demonstrated potent ability to activate cellular immunity thus prevent lung damage mice. This study provides new option broad vaccines against

Language: Английский

Development of a Recombinant Omicron BA.1 Subunit Vaccine Candidate in Pichia pastoris DOI Creative Commons
Sibel Kalyoncu,

Dogu Sayili,

Ayça Zeybek Kuyucu

et al.

Microbial Biotechnology, Journal Year: 2025, Volume and Issue: 18(1)

Published: Jan. 1, 2025

ABSTRACT Low‐cost and safe vaccines are needed to fill the vaccine inequity gap for future pandemics. Pichia pastoris is an ideal expression system recombinant protein production due its cost‐effective easy‐to‐scale‐up process. Here, we developed a next‐generation SARS‐CoV2 Omicron BA.1‐based candidate expressed in P. . The receptor binding domain of BA.1 spike (RBD‐Omicron) was produced at 0.35 g/L supernatant. With 60% recovery after two‐step purification, RBD‐Omicron showed 99% purity. After vitro characterisation purified via chromatography, mass spectrometry, calorimetry surface plasmon resonance‐based methods, it injected into mice immunization studies. Three different doses Alum CpG adjuvanted were investigated 10 μg gave highest antigenicity. two vaccination, IgG titers serum reached more than 6 These antibodies also recognized earlier (Delta Plus: B.1.617.2) later (Eris: EG.5, Pirola: BA.2.86) variants. long‐term immunological response measured by analyzing antibody T‐cell splenocytes 60 weeks. Interestingly, Th1 significantly high even year. subvariants dominantly circulating world, so sub‐lineage‐based can be used RBD‐Omicron‐based this study suitable technology transfer transition clinic.

Language: Английский

Citations

0
Vaccines reimagined: The peptide revolution in disease prevention DOI
Vivek P. Chavda

Progress in molecular biology and translational science, Journal Year: 2025, Volume and Issue: unknown, P. 329 - 354

Published: Jan. 1, 2025

Language: Английский

Citations

0
Oral delivery of protein and peptide therapeutics DOI
Vivek P. Chavda, Pankti C. Balar

Progress in molecular biology and translational science, Journal Year: 2025, Volume and Issue: unknown, P. 355 - 387

Published: Jan. 1, 2025

Language: Английский

Citations

0
Polyvalent immunoprotection of protein, DNA and IgY antibody vaccines of Vibrio fluvialis outer membrane protein VF08100 in fish DOI

Huihui Xiao,

Song Duan, Pan Cui

et al.

Fish & Shellfish Immunology, Journal Year: 2025, Volume and Issue: unknown, P. 110260 - 110260

Published: March 1, 2025

Language: Английский

Citations

0
AI in the development of vaccines for emerging and re-emerging diseases DOI
Rita Elizabeth Velastegui-Hernández, Verónica Gabriela Salinas Velasteguí, Diana Catalina Velasteguí Hernández

et al.

Salud Ciencia y Tecnología, Journal Year: 2025, Volume and Issue: 4

Published: Jan. 15, 2025

Introduction: The integration of artificial intelligence (AI) into vaccine development has revolutionized traditional methodologies, significantly enhancing the speed, precision, and scalability immunological research. Emerging re-emerging infectious diseases, driven by zoonotic spillovers, antimicrobial resistance, global environmental changes, pose substantial challenges. Addressing these requires innovative approaches, with AI playing a pivotal role in advancing solutions.Development: applications vaccinology include antigen detection, adjuvant optimization, immune response simulation. Deep learning algorithms streamline identification immunogenic targets conserved antigens, enabling for highly mutable pathogens such as SARS-CoV-2, HIV, influenza. Case studies demonstrate AI's transformative impact, including its rapid creation mRNA vaccines COVID-19, promising antigens malaria, enhanced efficacy influenza through predictive modeling. However, challenges unequal access to technology, biases data models, ethical concerns regarding genomic privacy persist. Recommendations address barriers increasing diversity, strengthening frameworks, investing infrastructure democratize AI-driven innovations.Conclusions: ability reduce time cost, improve enable personalized immunization strategies positions it cornerstone modern vaccinology. With continued advancements equitable implementation, holds potential reshape development, pandemic preparedness, longstanding public health disparities globally.

Language: Английский

Citations

0
Shortcomings of Current Adjuvants and Future Prospects DOI
Pankti C. Balar, Vasso Apostolopoulos, Vivek P. Chavda

et al.

Published: April 21, 2025

Language: Английский

Citations

0
Adjuvants Boosting Vaccine Effectiveness DOI
Vasso Apostolopoulos

Published: April 21, 2025

Language: Английский

Citations

0
A Self-Assembled Nanovaccine with BA.4/5 Receptor-Binding Domain and CpG Oligodeoxynucleotides Induces Broad-Spectrum Neutralization against SARS-CoV-2 Omicron Subvariants DOI

Chendong Yang,

Entao Li, Xiaoping Guo

et al.

ACS Nano, Journal Year: 2025, Volume and Issue: unknown

Published: April 23, 2025

Over the past 3 years, SARS-CoV-2 Omicron has been circulating globally with emergence of multiple subvariants, including BA.5, BA.5.2, XBB, XBB.1, EG.5.1, HK.3, BA.2.86, JN.1, and KP.2. To combat these several vaccines based on receptor-binding domain (RBD) dimers have developed; however, RBD dimer require frequent updates to cope new variants. In contrast, development a safe, effective, broad-spectrum vaccine against latest JN.1 KP.2, would be one-size-fits-all solution. Here, we designed BA.4/5 RBD-PC7A conjugate micelles by displaying in PC7A micelles. Remarkably, elicited potent neutralizing antibodies (NAbs) rabbits, effectively XBB.1.18, HK.3 infections. Moreover, alone were able induce NAbs mice BA.5 variant. When cytosine-phosphate-guanine (CpG) adjuvant was added electrostatically adsorbed micelles, there significant increase antibody titers IgG1, IgG2b, IgG2c. This enhancement facilitated broad neutralization various strains, Furthermore, CpG protected golden hamsters from infection BA.5.2 strain. study presents broadly nanovaccine that includes antigen adjuvant. It demonstrates efficacy highlighting its potential for clinical translation.

Language: Английский

Citations

0
Towards broad-spectrum protection: the development and challenges of combined respiratory virus vaccines DOI Creative Commons
Yang Wang, Xiaotong Wei, Yang Liu

et al.

Frontiers in Cellular and Infection Microbiology, Journal Year: 2024, Volume and Issue: 14

Published: June 5, 2024

In the post-COVID-19 era, co-circulation of respiratory viruses, including influenza, SARS-CoV-2, and syncytial virus (RSV), continues to have significant health impacts presents ongoing public challenges. Vaccination remains most effective measure for preventing viral infections. To address concurrent circulation these extensive efforts been dedicated development combined vaccines. These vaccines utilize a range platforms, mRNA-based vaccines, vector subunit providing opportunities in addressing multiple pathogens at once. This review delves into major advancements field vaccine research, underscoring strategic use various platforms tackle simultaneous viruses effectively.

Language: Английский

Citations

2
Non-Glycosylated SARS-CoV-2 Omicron BA.5 Receptor Binding Domain (RBD) with a Native-like Conformation Induces a Robust Immune Response with Potent Neutralization in a Mouse Model DOI Creative Commons

Rawiwan Wongnak,

Subbaian Brindha,

Mami Oba

et al.

Molecules, Journal Year: 2024, Volume and Issue: 29(11), P. 2676 - 2676

Published: June 5, 2024

The Omicron BA.5 variant of SARS-CoV-2 is known for its high transmissibility and capacity to evade immunity provided by vaccine protection against the (original) Wuhan strain. In our prior research, we successfully produced receptor-binding domain (RBD) spike protein in an E. coli expression system. Extensive biophysical characterization indicated that, even without glycosylation, RBD maintained native-like conformational properties. current study explores immunogenicity neutralization coli-expressed using a mouse model. Administration three doses any adjuvant elicited titer antisera up 7.3 × 105 1.6 106 after booster shot. Immunization with notably enhanced population CD44+CD62L+ T cells, indicating generation cell memory. vitro assays demonstrated antisera’s protective efficacy through significant inhibition interaction between human receptor, ACE2, potent pseudovirus. These findings underscore potential as viable candidate SARS-CoV-2.

Language: Английский

Citations

1